文献速递心境障碍

小胶质细胞ERK-NRBP1-CREB-BDNF信号在(R)-氯胺酮持续抗抑郁作用中的角色

Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine.
PubMed 文献 · Mol Psychiatry · 2021-11-24

该研究在小鼠慢性社会挫败应激(CSDS)模型中,通过iTRAQ鉴定出核受体结合蛋白1(NRBP1),并发现(R)-氯胺酮经小胶质细胞ERK激活上调NRBP1、BDNF及p-CREB/CREB比值,且其抗抑郁样效应可被CREB-HDO、BDNF exon IV-HDO、PLX3397或MCLs阻断。

要点

  • NRBP1定位于小鼠内侧前额叶皮层的小胶质细胞和神经元,不在星形胶质细胞。
  • (R)-氯胺酮经ERK激活上调原代小胶质细胞NRBP1、BDNF及p-CREB/CREB比值。
  • CREB-HDO、BDNF exon IV-HDO、PLX3397或MCLs均可阻断(R)-氯胺酮在CSDS易感小鼠中的抗抑郁样效应。

核心结论

  • 数据提示小胶质细胞中一条新的ERK-NRBP1-CREB-BDNF通路参与(R)-氯胺酮的抗抑郁样效应。

研究设计与样本

  • 采用慢性社会挫败应激(CSDS)小鼠模型,运用iTRAQ蛋白定量技术鉴定差异蛋白,并在原代小胶质细胞培养及CSDS易感小鼠中开展机制与干预实验。

主要发现

  • (R)-氯胺酮经ERK激活增加原代小胶质细胞中NRBP1、BDNF及p-CREB/CREB比值的表达。
  • 单次脑室内注射CREB-HDO或BDNF exon IV-HDO可阻断(R)-氯胺酮在CSDS易感小鼠中的抗抑郁样效应。
  • CSF1R抑制剂PLX3397耗竭小胶质细胞可阻断(R)-氯胺酮在CSDS易感小鼠中的抗抑郁样效应。
  • 单次脑室内注射MCLs抑制小胶质细胞可显著阻断(R)-氯胺酮在CSDS易感小鼠中的抗抑郁样效应。
  • 单次脑室内注射CREB-HDO、BDNF exon IV-HDO或MCLs可阻断(R)-氯胺酮对CSDS易感小鼠mPFC降低的树突棘密度的改善作用。

关键数值与推荐

  • NRBP1定位于小鼠内侧前额叶皮层的小胶质细胞和神经元,而非星形胶质细胞。
  • (R)-氯胺酮在原代小胶质细胞培养中经ERK激活上调NRBP1、BDNF及p-CREB/CREB比值。
  • (R)-氯胺酮通过激活CREB及抑制MeCP2促进小胶质细胞中BDNF转录。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

(R,S)-ketamine elicits rapid-acting and sustained antidepressant actions in treatment-resistant patients with depression. (R)-ketamine produces longer-lasting antidepressant effects than (S)-ketamine in rodents; however, the precise molecular mechanisms underlying antidepressant actions of (R)-ketamine remain unknown. Using isobaric Tag for Relative and Absolute Quantification, we identified nuclear receptor-binding protein 1 (NRBP1) that could contribute to different antidepressant-like effects of the two enantiomers in chronic social defeat stress (CSDS) model. NRBP1 was localized in the microglia and neuron, not astrocyte, of mouse medial prefrontal cortex (mPFC). (R)-ketamine increased the expression of NRBP1, brain-derived neurotrophic factor (BDNF), and phosphorylated cAMP response element binding protein (p-CREB)/CREB ratio in primary microglia cultures thorough the extracellular signal-regulated kinase (ERK) activation. Furthermore, (R)-ketamine could activate BDNF transcription through activation of CREB as well as MeCP2 (methyl-CpG binding protein 2) suppression in microglia. Single intracerebroventricular (i.c.v.) injection of CREB-DNA/RNA heteroduplex oligonucleotides (CREB-HDO) or BDNF exon IV-HDO blocked the antidepressant-like effects of (R)-ketamine in CSDS susceptible mice. Moreover, microglial depletion by colony-stimulating factor 1 receptor (CSF1R) inhibitor PLX3397 blocked the antidepressant-like effects of (R)-ketamine in CSDS susceptible mice. In addition, inhibition of microglia by single i.c.v. injection of mannosylated clodronate liposomes (MCLs) significantly blocked the antidepressant-like effects of (R)-ketamine in CSDS susceptible mice. Finally, single i.c.v. injection of CREB-HDO, BDNF exon IV-HDO or MCLs blocked the beneficial effects of (R)-ketamine on the reduced dendritic spine density in the mPFC of CSDS susceptible mice. These data suggest a novel ERK-NRBP1-CREB-BDNF pathways in microglia underlying antidepressant-like effects of (R)-ketamine.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Yao W, Cao Q, Luo S, et al. Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine. Mol Psychiatry. 2021. PMID: 34819637. doi:10.1038/s41380-021-01377-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。